Pembrolizumab, Decitabine +/- Venetoclax

Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
54 patients (estimated)
Sponsors
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Tags
BCL-2 Inhibitor, Checkpoint Inhibitor, Hypomethylating Agents (HMA), Monoclonal Antibody, Programmed Death Receptor-1 (PD-1), Doublet Therapy
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1516
NCT Identifier
NCT03969446

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.